Process of preparing alcaftadine

ABSTRACT

The present invention is related to pure compound of structural formula (VIII), process for the purification of compound of structural formula (VIII) and improved process of preparing alcaftadine compound of structural formula (I).

FIELD OF THE INVENTION

The field relates to an improved process of preparing substantially pure alcaftadine comprising reacting compound of structural formula VIII with more than 20 moles of oxidizing reagent in an organic solvent to get alcaftadine. The field also relates to a process of preparing alcaftadine compound of structural formula I by employing substantially pure compound of structural formula VIII.

BACKGROUND OF THE INVENTION

Alcaftadine is chemically 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5H-imidazo[2,1-b][3]benzazepine-3-carboxaldehyde and is known from U.S. Pat. No. 5,468,743 and is represented by a compound of structural formula I:

Alcaftadine is a H₁ histamine receptor antagonist sold in USA under the proprietary name of “LASTACAFT” and is indicated for the prevention of itching associated with allergic conjunctivitis.

U.S. Pat. No. 5,468,743 describes analogous processes of preparing alcaftadine compound of structural formula I as shown below in scheme no. I, scheme no. II and scheme no. III:

The processes of preparing compound of structural formula VIII according to the above mentioned references produce more than 25% of compound of structural formula XIV:

The compound of structural formula XIV is being carry-forwarded into the further steps of reactions of preparing alcaftadine compound of structural formula I and therefore there is a need in the art to develop an improved process of preparing compound of structural formula VIII, which obviates the prior-art problems.

Further, the prior art processes for preparing alcaftadine compound of structural formula I comprises treating compound of structural formula VIII with less than 20 moles of oxidizing reagent which leads to incomplete reaction and causes low yield of alcaftadine.

Accordingly, there is a need in the art to develop an improved process of preparing alcaftadine compound of structural formula I, which obviates the prior-art problems.

The inventors of the present invention have developed an improved process for the preparation of alcaftadine using substantially pure compound or purified compound of structural formula VIII, resulting in higher yield of alcaftadine. The improved process is cost effective and has fewer steps as compared to the process disclosed in the prior publications.

Further, the inventors have found that treating compound of structural formula VIII with more than 20 moles of oxidizing reagent leads to completion of reaction and results in higher yield of alcaftadine.

SUMMARY OF THE INVENTION

First aspect of the present invention is to provide a substantially pure compound of structural formula VIII:

According to another aspect, the present invention relates to process for the purification of compound of structural formula VIII.

According to another aspect, the present invention relates to a process for purification of compound of structural formula VIII comprising the steps of:

-   -   a. dissolving crude compound of structural formula VIII in an         ether solvent and,     -   b. isolating substantially pure compound of structural formula         VIII.

According to another aspect, the present invention relates to a process of preparing alcaftadine compound of structural formula I comprising the steps of:

-   -   a. dissolving crude compound of structural formula VIII in an         ether solvent,     -   b. isolating substantially pure compound of structural formula         VIII and     -   c. converting substantially pure compound of structural formula         VIII into alcaftadine compound of structural formula I.

According to another aspect, the present invention relates to solvated compound of structural formula XV:

According to another aspect, the present invention relates to tetrahydrofuran solvated compound of structural formula XVI:

According to another aspect, the present invention relates to a crystalline compound of structural formula VIII.

Another aspect of the present invention is to provide an improved process of preparing alcaftadine compound of structural formula I.

Another aspect of the present invention is to provide an improved process of preparing alcaftadine comprising reacting compound of structural formula VIII with more than 20 moles of oxidizing reagent in an organic solvent to get alcaftadine compound of structural formula I:

Another aspect of the present invention is to provide substantially pure alcaftadine compound of structural formula I.

Another aspect of the present invention is to provide a process of preparing, substantially pure alcaftadine compound of structural formula I comprising reacting compound of structural formula VIII with more than 20 moles of oxidizing reagent in an organic solvent to get substantially pure alcaftadine compound of structural formula I.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts X-ray diffraction pattern of crystalline compound of structural formula VIII.

FIG. 2 depicts Infra-Red spectra of crystalline compound of structural formula VIII.

DETAILED DESCRIPTION OF THE INVENTION

The examples and drawings provided in the detailed description are merely examples, and should not be used to limit the scope of the claims in any claim construction or interpretation.

In an embodiment the present invention relates to a process for the preparation of substantially pure compound of structural formula VIII:

The term “substantially pure compound of structural formula VIII” described herein referred to compound of structural formula VIII having less than 15% of compound of structural formula XIV:

In another embodiment, the present invention relates to a process for purification of compound of structural formula VIII comprising the steps of:

-   -   a. dissolving crude compound of structural formula VIII in an         ether solvent and,     -   b. isolating substantially pure compound of structural formula         VIII.

The crude compound of structural formula VIII used according to the present invention can be prepared by methods disclosed in the art such as those described in U.S. Pat. No. 5,468,743, the disclosure of which is incorporated herein by reference.

The purification of compound of structural formula VIII is carried out by dissolving crude compound of structural formula VIII in an ether solvent at a temperature in the range of 40° C. to 80° C. and maintained for 30 minutes to 2 hours. The resulting solution was cooled to 20° C. to 30° C. to get pure compound of structural formula VIII.

Ether solvents can be selected from the group comprising, but not limited to, tetrahydrofuran, 1,4-dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether or mixture(s) thereof.

The substantially pure compound of structural formula VIII may be isolated by any known process in the at such as filtration, centrifugation, washing, drying or the combinations thereof.

The isolated pure compound of structural formula VIII may be dried at a temperature in the range of 40° C. to 80° C. for a period of 2 horns to 12 hours under reduced pressure.

The solvates of compound of structural formula XV can be selected from the group comprising, but not limited to, tetrahydrofuran solvate, 1,4-dioxane solvate, diethyl ether solvate, diisopropyl ether solvate, dibutyl ether solvate, methyl tertiary butyl ether solvate, methyl ethyl ether solvate or methyl isobutyl ether solvate.

The example of solvated compound of structural formula XV may include tetrahydrofuran solvated compound of structural formula XVI:

The isolated substantially pure compound of structural formula VIII may be crystalline or amorphous in nature.

In another embodiment, the present invention relates to a crystalline compound of structural formula VIII characterized by X-ray diffraction pattern having peaks at 8.0, 11.0, 12.8, 14.0, 15.0, 15.7, 16.9, 18.7, 19.3, 20.3, 20.6, 21.8, 22.2, 22.6, 25.2, 25.8, 27.1, 27.8, 28.8, 30.7±0.2 degrees two theta.

In another embodiment, the present invention relates to a crystalline compound of structural formula VIII characterized by X-ray diffraction pattern as depicted in FIG. 1.

In another embodiment, the present invention relates to a crystalline compound of structural formula VIII characterized by Infra-Red spectrum as depicted in FIG. 2.

In one example, the alcaftadine compound of structural formula I is prepared by reacting compound of structural formula VIII with more than 20 moles of oxidizing reagent in an organic solvent.

In another embodiment, the present invention relates to a process of preparing alcaftadine compound of structural formula I comprising, the steps of:

-   -   a. dissolving crude compound of structural formula VIII in an         ether solvent,     -   b. isolating substantially pure compound of structural formula         VIII and     -   c. Converting substantially pure compound of structural formula         VIII into alcaftadine compound of structural formula I.

In another embodiment, the present invention relates to a process of preparing substantially pure alcaftadine compound of structural formula I comprising reacting compound of structural formula VIII with more than 20 moles of oxidizing reagent in an organic solvent to get substantially pure alcaftadine compound of structural formula I.

The reaction of compound of structural formula VIII with more than 20 moles of oxidizing reagent in an organic solvent can be carried out at a temperature in the range of 40° C. to 80° C. for a period of 2 hours to 24 hours.

The oxidizing reagent may be added in one lot or in several lots.

Oxidizing reagent can be selected from the group comprising, but not limited to, manganese dioxide, silver nitrate, selenium dioxide or eerie ammonium nitrate or the like or mixtures thereof.

Organic solvent according to present invention can be selected from the group comprising, but not limited to, ketones, alcohols, esters, nitriles, halogenated aliphatic hydrocarbon solvents, ethers or mixtures thereof.

The ketone solvents can be selected from the group comprising, but not limited to, acetone, methyl ethyl ketone, methyl isobutyl ketone, dibutyl ketone, diethyl ketone, dipropyl ketone, diisopropyl ketone, methyl butyl ketone, methyl propyl ketone, methyl isopropyl ketone, ethyl isopropyl ketone or mixture(s) thereof.

The alcohol solve can be selected from the group comprising, but not limited to, methanol, ethanol, propanol, isopropanol, butanol, isobutanol, t-butanol, pentanol or mixture(s) thereof.

The ester solvents can be select from the group comprising, but not limited ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, tertiary butyl acetate, pentyl acetate or mixture(s) thereof.

The nitrile solvents can be selected from the group comprising, but not limited to, acetonitrile, propionitrile or mixture(s) thereof.

The halogenated aliphatic hydrocarbon solvents can be selected from the group comprising, but not limited to, dichloromethane, dichloroethane, chloroform, carbon tetrachloride or mixture(s) thereof.

The ether solvents can be selected from the group comprising, but not limited to, tetrahydrofuran, dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether or mixture(s) thereof.

The alcaftadine compound of structural formula I can be isolated by cooling the reaction mixture at a temperature in the range of 25-35° C. followed by filtering the reaction mixture to get filtrate. The filtrate obtained may be washed with organic solvent and then organic layer can be separated, washed with water and dried over sodium sulphate.

The resulting organic layer containing alcaftadine compound of structural formula I may be concentrated under reduced pressure to get residue of alcaftadine compound of structural formula I. The residue of alcaftadine compound of structural formula I may be crystallized by an ether solvent to et substantially pure alcaftadine compound of structural formula I.

The isolated substantially pure alcaftadine compound structural formula I may be dried at a temperature in the range of 40-60° C. for a period of 2 hours to 10 hours under reduced pressure.

The term “substantially pure alcaftadine compound of structural formula I” described herein refers to an alcaftadine compound of structural formula I having less than 5% of compound of structural formula VIII:

EXAMPLES

In the following examples, the preferred embodiments of the present invention are described only by way of illustrating the process of the invention. However, these are not intended to limit the scope of the present invention in any way.

Example 1 Purification of Compound of Structural Formula VIII

A crude compound of structural formula VIII (50 gm) was dissolved in tetrahydrofuran (500 ml) at 60-65° C. and maintained for 1 hour. The resulting solution was cooled to 25-35° C. to get solid. The resulting solids were filtered, washed with tetrahydrofuran (50 ml) and dried, at 45-55° C. under reduced pressure for 8 hours to get pure compound of structural formula VIII.

Yield: 35 gm

Purity: 99.9% (By HPLC)

Example 2 Purification of Compound of Structural Formula VIII

A crude compound of structural formula VIII (10 gm) was dissolved in tetrahydrofuran (100 ml) at 60-65° C. and maintained for 1 hour. The resulting solution was cooled to 25-35° C. to get solid. The resulting solids were filtered, washed with tetrahydrofuran (10 ml) and dried at 45-55° C. under reduced pressure for 5 hours to get pure compound of structural formula VIII.

Yield: 8.5 gm

Purity: 99.9% (By HPLC)

Example 3 Purification of Compound of Structural Formula VIII

A crude compound of structural formula VIII (10 gm) was dissolved in 1,4-dioxane (100 ml) at 60-65° C. and maintained for 1 hour. The resulting solution was cooled to 25-35° C. to get solid. The resulting solids were filtered, washed with 1,4-dioxane (20 ml) and dried at 45-55° C. under reduced pressure for 6 hours to get pure compound of structural formula VIII.

Yield: 8.7 gm

Purity: 99.8% (By HPLC)

Example 4 Preparation of Substantially Pure Alcaftadine Compound of Structural Formula I

The solution of compound of structural formula VIII (410 gm) in chloroform (4000 ml) was added first lot of manganese dioxide (200 gm) at 25-35° C. and then the resulting reaction mixture was heated to 60-65° C. and stirred for 4 hours. The second lot of manganese dioxide (200 gm) was then added to the reaction mixture at 60-65° C. and stirred fix 4 hours. In this manner third, fourth, fifth and sixth lot of manganese dioxide (200 gm) was added to the reaction mixture at 60-65° C. after each lot addition reaction mixture stirred for 4 hours. The resulting reaction mixture was cooled to 25-35° C., filtered and washed with chloroform (1000 ml). The resulting organic layer was washed with water (2×400 ml), dried over sodium sulphate (200 gm) and concentrated under reduced pressure to get residue. The resulting residue was added diethyl ether (150 ml) and stirred for 2 hours at 25-35° C. to get suspension. The resulting suspension was filtered, wash with diethyl ether (50 ml) and dried under reduced pressure at 45-55° C. for 8 hours to get title compound.

Yield: 30 gm

Purity: 98.7% (By HPLC)

Example 5 Preparation of Substantially Pure Alcaftadine Compound of Structural Formula I

The solution of compound of structural formula VIII (20 gm) in chloroform (2000 ml) was added manganese dioxide (600 gm) at 25-35° C. and then the resulting reaction mixture was heated to 60-65° C. and stirred for 18 hours. The resulting reaction mixture was cooled to 25-35° C., filtered and washed with chloroform (500 ml). The resulting organic layer was washed with water (2×200 ml), dried over sodium sulphate (100 gm) and concentrated under reduced pressure to get residue. The resulting residue was added diethyl ether (100 ml) and stirred for 1 hours at 25-35° C. to get suspension. The resulting suspension was filtered, wash with diethyl ether (25 ml) and dried under reduced pressure at 45-55° C. for 6 hours to get title compound.

Yield: 15 gm

Purity: 98.8% (By HPLC)

Example 6 Preparation of Substantially Pure Alcaftadine Compound of Structural Formula I

The solution of compound of structural formula VIII (40 gm) in chloroform (4000 ml) was added manganese dioxide (1200 gm) at 25-35° C. and then the resulting reaction mixture was heated to 60-65° C. and stirred flu 16 hours. The resulting reaction mixture was cooled to 25-35° C., filtered and washed with chloroform (1000 ml). The resulting organic layer was washed with water (2×400 ml), dried over sodium sulphate (200 gm) and concentrated under reduced pressure to get residue. The resulting residue was added diethyl ether (200 ml) and stirred for 1 hours at 25-35° C. to get suspension. The resulting suspension was filtered, wash with diethyl ether (50 ml) and dried under reduced pressure at 45-55° C. for 8 hours to get title compound.

Yield: 30 gm

Purity: 98.9% (By HPLC)

The scope of the claims should not be limited by the preferred embodiments and examples, but should be given the broadest interpretation consistent with the specification as a whole. 

1. A process of purification of compound of structural formula VIII comprising the steps of: a) dissolving crude compound of structural formula VIII in an ether solvent; and b) isolating a substantially pure compound of structural formula VIII:


2. The process according to claim 1, wherein the crude compound of structural formula VIII was dissolved at a temperature in the range of 40° C. to 80° C., maintained for 30 minutes to 2 hours, and then cooled to 20° C. to 30° C. to get a pure compound of structural formula VIII.
 3. The process according to claim 1, wherein the ether solvent is selected from the group consisting of tetrahydrofuran, 1,4-dioxane, diethyl ether, diisopropyl ether, dibutyl ether, methyl tertiary butyl ether, methyl ethyl ether, methyl isobutyl ether and mixture(s) thereof.
 4. The process according to claim 1, wherein the pure compound of structural formula VIII is isolated by the steps of filtration, centrifugation, washing, drying or combinations thereof.
 5. The process according to claim 4, wherein the isolated pure compound of structural formula VIII is dried at a temperature in the range of 40° C. to 80° C. for a period of 2 hours to 12 hours under reduced pressure.
 6. The process according to claim 1, wherein the substantially pure compound of structural formula VIII, is having less than 15% of a compound of structural formula XIV:


7. A solvated compound of structural formula XV having the formula:


8. The compound according to claim 7, wherein the solvated compound of structural formula XV is selected from the group consisting of tetrahydrofuran solvate, 1,4-dioxane solvate, diethyl ether solvate, diisopropyl ether solvate, dibutyl ether solvate, methyl tertiary butyl ether solvate, methyl ethyl ether solvate and methyl isobutyl ether solvate.
 9. (canceled)
 10. (canceled)
 11. (canceled)
 12. (canceled)
 13. A process of preparing an alcaftadine compound of structural formula I comprising the steps of: a) dissolving crude compound of structural formula VIII in an ether solvent; b) isolating a substantially pure compound of structural formula VIII; and c) converting the substantially pure compound of structural formula VIII into an alcaftadine compound of structural formula I.
 14. (canceled)
 15. (canceled)
 16. (canceled)
 17. (canceled)
 18. (canceled)
 19. (canceled)
 20. (canceled)
 21. (canceled) 